Search results

626 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Public health guidelines Remove Public health guidelines filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Quality standards Remove Quality standards filter

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Atrial fibrillation - vernakalant [ID454]

In development [GID-TAG428] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Conjunctivitis: antimicrobial prescribing

In development [GID-NG10166] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Minimally invasive meshless and dissectionless anchoring system for pelvic organ prolapse repair

In development [GID-IPG10191] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Superfcial vein arterialisation and selective venous embolisation for critical limb ischaemia

In development [GID-IPG10192] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Percutaneous endovascular forearm-arteriovenous fistula creation for haemodialysis access

In development [GID-IPG10193] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Tunnelled peritoneal drainage catheter insertion for treatment-resistant, recurrent ascites due to cirrhosis

In development [GID-IPG10194] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Regional nerve graft to restore corneal sensation

In development [GID-IPG10195] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Supercapsular Percutaneously Assisted Total Hip replacement for osteoarthritis

In development [GID-IPG10196] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Insertion of aortic arch remodelling graft as an adjunct to surgical repair of acute aortic dissection

In development [GID-IPG10197] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Percutaneous thoracic duct embolization for chyle leak

In development [GID-IPG10201] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Focal articular prosthetic resurfacing for treating articular cartilage defects in the knee

In development [GID-IPG10202] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Transcatheter tricuspid valve reconstruction for tricuspid regurgitation

In development [GID-IPG10198] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Sternoclavicular joint replacement for arthritis

In development [GID-IPG10199] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
External electrical muscle stimulation for urinary incontinence

In development [GID-IPG10200] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Reducing sexually transmitted infections

In development [GID-NG10142] Expected publication date: 09 February 2022

Type

NICE guideline

Status

In development
Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]

In development [GID-TA10759] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia [ID2708]

In development [GID-TA10588] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

In development [GID-TA10539] Expected publication date: 15 December 2021

Type

Technology appraisal guidance

Status

In development
Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids

In development [GID-IPG10147] Expected publication date: 31 March 2021

Type

Interventional procedures guidance

Status

In development
Extracorporeal whole liver perfusion for acute liver failure

In development [GID-IPG10164] Expected publication date: 31 March 2021

Type

Interventional procedures guidance

Status

In development
Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

In development [GID-TA10566] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412]

In development [GID-TA10398] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

In development [GID-TA10633] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

In development [GID-TA10202] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683

In development [GID-TA10537] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]

In development [GID-TA10760] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]

In development [GID-TA10761] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

In development [GID-TA10577] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]

In development [GID-TA10523] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer

In development [GID-IPG10205] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)

In development [GID-IPG10203] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Total hip arthroplasty using the superpath approach for osteoarthritis

In development [GID-IPG10204] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
OraQuick® HCV Rapid Antibody Test (discontinued)

In development [GID-MT117] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
LJ TEST

In development [GID-TA10462] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288

In development [GID-TA10212] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

In development [GID-TA10271] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

In development [GID-TA10575] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Spasticity (after stroke) - botulinum toxin type A [ID768]

In development [GID-TAG499] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

In development [GID-TA10105] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

In development [GID-TA10089] Expected publication date: 15 November 2017

Type

Technology appraisal guidance

Status

In development
DHT pilot: myCOPD for self-management of chronic obstructive pulmonary disease (COPD)

In development [GID-MT531] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 02 March 2021

Type

Antimicrobial prescribing guideline

Status

In development
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

In development [GID-TA10458] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Eculizumab for treating relapsing neuromyelitis optica [ID1271]

In development [GID-TA10469] Expected publication date: 02 September 2020

Type

Technology appraisal guidance

Status

In development
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179

In development [GID-TA10450] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]

In development [GID-TA10430] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea ID1065

In development [GID-TA10385] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712]

In development [GID-TA10572] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development